Natural Products to Overcome Targeted Therapy Resistance in Acute Myeloid Leukemia: Mechanisms, Molecular Targets, and Translational Opportunities

Abstract Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by uncontrolled proliferation of immature myeloid cells and remains associated with poor clinical outcomes despite recent therapeutic advances. The introduction of the BCL-2 inhibitor venetoclax has significantly improved response rates, particularly in combination with hypomethylating agents, yet primary and acquired resistance frequently limits durable remission. Mechanisms underlying resistance include apoptotic rewiring; overexpression of MCL-1 and BCL-XL; activation of PI3K/AKT/mTOR, MAPK, NF-κB, and STAT3 signaling; metabolic reprogramming; leukemia stem-cell persistence; epigenetic dysregulation; and protective interactions within the bone marrow microenvironment. Natural products represent a promising source of multitarget therapeutic agents capable of modulating diverse oncogenic networks involved in AML progression and drug resistance. This review comprehensively summarizes the antileukemic potential of phytochemicals including curcumin, parthenolide, resveratrol, quercetin, honokiol, matrine, wogonin, withanolides, homoharringtonine, avocatin B, ajoene, and apigenin. Particular emphasis is placed on their ability to induce apoptosis, eradicate leukemia stem cells, suppress metabolic adaptations, trigger ferroptosis, reverse epigenetic abnormalities, and remodel the tumor microenvironment. We critically evaluate the evidence supporting these mechanisms and discuss translational opportunities, combination strategies, formulation advances, and current challenges related to bioavailability, pharmacokinetics, and biomarker-guided patient selection. We propose that natural products, when integrated into precision medicine frameworks and advanced delivery systems, offer substantial potential as adjunctive therapies for overcoming venetoclax resistance. However, successful clinical translation requires rigorous pharmacokinetic optimization, biomarker-guided patient stratification, and well-designed clinical trials.

Authors

Institutions

Publication Details

Journal
ACS Pharmacology & Translational Science
Published
2026-11-12
DOI
https://doi.org/10.1021/acsptsci.6c00528
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Natural Products to Overcome Targeted Therapy Resistance in Acute Myeloid Leukemia: Mechanisms, Molecular Targets, and Translational Opportunities

Amit Singh, Arpit Sharma, Shruti S. Raut, Alok Shukla et al.
ACS Pharmacology & Translational Science
Acute Myeloid Leukemia Research
article

Natural Products to Overcome Targeted Therapy Resistance in Acute Myeloid Leukemia: Mechanisms, Molecular Targets, and Translational Opportunities

Amit Singh, Arpit Sharma, Shruti S. Raut, Alok Shukla, Abha Mishra, Pooja Yadav
article en

Abstract

Abstract Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by uncontrolled proliferation of immature myeloid cells and remains associated with poor clinical outcomes despite recent therapeutic advances. The introduction of the BCL-2 inhibitor venetoclax has significantly improved response rates, particularly in combination with hypomethylating agents, yet primary and acquired resistance frequently limits durable remission. Mechanisms underlying resistance include apoptotic rewiring; overexpression of MCL-1 and BCL-XL; activation of PI3K/AKT/mTOR, MAPK, NF-κB, and STAT3 signaling; metabolic reprogramming; leukemia stem-cell persistence; epigenetic dysregulation; and protective interactions within the bone marrow microenvironment. Natural products represent a promising source of multitarget therapeutic agents capable of modulating diverse oncogenic networks involved in AML progression and drug resistance. This review comprehensively summarizes the antileukemic potential of phytochemicals including curcumin, parthenolide, resveratrol, quercetin, honokiol, matrine, wogonin, withanolides, homoharringtonine, avocatin B, ajoene, and apigenin. Particular emphasis is placed on their ability to induce apoptosis, eradicate leukemia stem cells, suppress metabolic adaptations, trigger ferroptosis, reverse epigenetic abnormalities, and remodel the tumor microenvironment. We critically evaluate the evidence supporting these mechanisms and discuss translational opportunities, combination strategies, formulation advances, and current challenges related to bioavailability, pharmacokinetics, and biomarker-guided patient selection. We propose that natural products, when integrated into precision medicine frameworks and advanced delivery systems, offer substantial potential as adjunctive therapies for overcoming venetoclax resistance. However, successful clinical translation requires rigorous pharmacokinetic optimization, biomarker-guided patient stratification, and well-designed clinical trials.

ACS Pharmacology & Translational Science
Institute of Medical Sciences (IN), Indian Institute of Technology BHU (IN), Indian Institute of Technology Indore (IN), Banaras Hindu University (IN)
Indian Council of Medical Research, Indian Institute of Technology (BHU) Varanasi
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon